[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800-466-6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 70, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 62, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1006234, "exercisedValue": 0, "unexercisedValue": 228334}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 62, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 677467, "exercisedValue": 0, "unexercisedValue": 52440}, {"maxAge": 1, "name": "Ms. Kristina  Engeseth M.B.A.", "title": "Senior VP and Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 57, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "Senior VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hardean E. Achneck M.D.", "age": 47, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.05, "open": 6.24, "dayLow": 6.18, "dayHigh": 7.4591, "regularMarketPreviousClose": 6.05, "regularMarketOpen": 6.24, "regularMarketDayLow": 6.18, "regularMarketDayHigh": 7.4591, "payoutRatio": 0.0, "beta": 2.691, "forwardPE": -0.60402685, "volume": 256715, "regularMarketVolume": 256715, "averageVolume": 158739, "averageVolume10days": 121670, "averageDailyVolume10Day": 121670, "bid": 5.23, "ask": 8.02, "bidSize": 2, "askSize": 2, "marketCap": 44026560, "fiftyTwoWeekLow": 3.76, "fiftyTwoWeekHigh": 46.8, "priceToSalesTrailing12Months": 13.463779, "fiftyDayAverage": 5.6768, "twoHundredDayAverage": 15.824775, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -85960432, "profitMargins": 0.0, "floatShares": 2941280, "sharesOutstanding": 5314800, "sharesShort": 640196, "sharesShortPriorMonth": 831999, "sharesShortPreviousMonthDate": 1744675200, "dateShortInterest": 1747267200, "sharesPercentSharesOut": 0.1047, "heldPercentInsiders": 0.10441, "heldPercentInstitutions": 0.65641, "shortRatio": 4.06, "shortPercentOfFloat": 0.123100005, "impliedSharesOutstanding": 6357370, "bookValue": 19.043, "priceToBook": 0.3780917, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -53260000, "trailingEps": -17.47, "forwardEps": -11.92, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": -26.288, "enterpriseToEbitda": 1.006, "52WeekChange": -0.46666664, "SandP52WeekChange": 0.119305134, "quoteType": "EQUITY", "currentPrice": 7.2, "targetHighPrice": 175.0, "targetLowPrice": 36.0, "targetMeanPrice": 90.33333, "targetMedianPrice": 60.0, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 137860992, "totalCashPerShare": 22.545, "ebitda": -85412000, "totalDebt": 7874000, "quickRatio": 7.276, "currentRatio": 7.558, "totalRevenue": 3270000, "debtToEquity": 6.762, "revenuePerShare": 0.481, "returnOnAssets": -0.38743, "returnOnEquity": -0.6044, "grossProfits": -65135000, "freeCashflow": -44940376, "operatingCashflow": -78906000, "revenueGrowth": -0.685, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -61.8746, "financialCurrency": "USD", "symbol": "ALGS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Aligos Therapeutics, Inc.", "marketState": "CLOSED", "longName": "Aligos Therapeutics, Inc.", "ipoExpectedDate": "2020-10-16", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1749251493, "regularMarketTime": 1749240001, "exchange": "NCM", "messageBoardId": "finmb_581475891", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "postMarketChangePercent": 0.0, "postMarketPrice": 7.2, "postMarketChange": 0.0, "regularMarketChange": 1.15, "regularMarketDayRange": "6.18 - 7.4591", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 158739, "fiftyTwoWeekLowChange": 3.4399998, "fiftyTwoWeekLowChangePercent": 0.91489357, "fiftyTwoWeekRange": "3.76 - 46.8", "fiftyTwoWeekHighChange": -39.6, "fiftyTwoWeekHighChangePercent": -0.84615386, "fiftyTwoWeekChangePercent": -46.666664, "earningsTimestamp": 1746532800, "earningsTimestampStart": 1754305140, "earningsTimestampEnd": 1754654400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -17.47, "epsForward": -11.92, "epsCurrentYear": -6.695, "priceEpsCurrentYear": -1.0754293, "fiftyDayAverageChange": 1.5232, "fiftyDayAverageChangePercent": 0.2683202, "twoHundredDayAverageChange": -8.624775, "twoHundredDayAverageChangePercent": -0.54501724, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1602855000000, "regularMarketChangePercent": 19.0083, "regularMarketPrice": 7.2, "displayName": "Aligos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-06-07"}]